Mandate

Vinge advises Industrifonden in connection with an investment in Cellevate

July 03, 2023 M&A

Vinge has advised Industrifonden in connection with its investment in Cellevate. Cellevate is an innovative biotech company that develops the next generation of cell culture systems.

Vinge’s team primarily consisted of Johan Larsson, Ellinor Wargenbrant and Stojan Arnerstål

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026